GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Debt-to-EBITDA

TNXP (Tonix Pharmaceuticals Holding) Debt-to-EBITDA : -0.10 (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Tonix Pharmaceuticals Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $3.09 Mil. Tonix Pharmaceuticals Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $5.03 Mil. Tonix Pharmaceuticals Holding's annualized EBITDA for the quarter that ended in Dec. 2024 was $-84.23 Mil. Tonix Pharmaceuticals Holding's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -0.10.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Tonix Pharmaceuticals Holding's Debt-to-EBITDA or its related term are showing as below:

TNXP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.11   Med: -0.02   Max: -0.01
Current: -0.11

During the past 13 years, the highest Debt-to-EBITDA Ratio of Tonix Pharmaceuticals Holding was -0.01. The lowest was -0.11. And the median was -0.02.

TNXP's Debt-to-EBITDA is ranked worse than
100% of 273 companies
in the Biotechnology industry
Industry Median: 1.54 vs TNXP: -0.11

Tonix Pharmaceuticals Holding Debt-to-EBITDA Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Debt-to-EBITDA Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.01 -0.01 -0.09 -0.11

Tonix Pharmaceuticals Holding Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.12 -0.14 -0.16 -0.10

Competitive Comparison of Tonix Pharmaceuticals Holding's Debt-to-EBITDA

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tonix Pharmaceuticals Holding's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Debt-to-EBITDA falls into.


;
;

Tonix Pharmaceuticals Holding Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Tonix Pharmaceuticals Holding's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.094 + 5.025) / -71.729
=-0.11

Tonix Pharmaceuticals Holding's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.094 + 5.025) / -84.232
=-0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Tonix Pharmaceuticals Holding  (NAS:TNXP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Tonix Pharmaceuticals Holding Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Tonix Pharmaceuticals Holding Business Description

Traded in Other Exchanges
N/A
Address
26 Main Street, Suite 101, Chatham, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
Executives
Richard Newcomb Stillwell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman director, 10 percent owner, officer: Chief Executive Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco director C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan officer: Chief Medical Officer C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange director
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris officer: Chief Administrative Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes director 74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304